Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/42127
Conference/Presentation Title: | Intravitreal triamcinolone: Efficacy and complications of different methods of drug delivery. | Authors: | Young S.;Chilov M.;Fraser-Bell S.;Harper A.;Cheng N.;Zamir E.;Dunlop A.;Stawell R.;Hall A.;Michalova K.;Lim L.;Hodgson L.;Glatz E. | Institution: | (Cheng, Zamir, Stawell, Harper, Glatz, Hodgson, Lim) Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia (Cheng) Royal Melbourne Hospital, Melbourne, VIC, Australia (Harper, Glatz, Hodgson, Lim) Centre for Eye Research Australia, Melbourne, VIC, Australia (Zamir) Melbourne Eye Specialists, Melbourne, VIC, Australia (Stawell, Hall) Eye Surgery Associ., Melbourne, VIC, Australia (Hall) Alfred Hospital, Melbourne, VIC, Australia (Fraser-Bell) Sydney Eye Hospital, Sydney, NSW, Australia (Chilov) Retina Associ., Sydney, NSW, Australia (Young) Gladesville Retina, Sydney, NSW, Australia (Michalova) Cranbourne Eye Surgery, Melbourne, VIC, Australia (Michalova) Monash Health, Melbourne, VIC, Australia (Dunlop) Care Foresight, Newcastle, NSW, Australia | Presentation/Conference Date: | 10-Jul-2015 | Copyright year: | 2014 | Publisher: | Blackwell Publishing | Publication information: | Clinical and Experimental Ophthalmology. Conference: 46th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists. Brisbane, QLD Australia. Conference Publication: (var.pagings). 42 (SUPPL. 1) (pp 17), 2014. Date of Publication: November 2014. | Abstract: | Purpose: The aim of this study was to assess the efficacy and complication rates of different methods of IVTA delivery, specifically, Triesence (Alcon Laboratories) and Kenacort A-40 (Aspen Pharma). Method(s): Members of the RANZCO Uveitis Special interest group were invited to take part in a prospective, online IVTA audit via a secure online platform. Main outcomes assessed included visual acuity (VA), central macular thickness (CMT) and incidence of complications. Result(s): 138 Triesence and 60 Kenacort injections from 91 patients (mean age 64 years) were recorded from January 2012 to June 2014 in 7 ophthalmic practices across Australia. The most common indications for treatment were diabetic macular oedema (45.7%), uveitis (29.8%), pseudophakic macular oedema (7.4%) and retinal vein occlusion (7.4%). The mean CMT at time of first injection was 461 mum +/- 176 in the Triesence group and 473 mum +/- 165 in the Kenacort group, with mean logMAR VA of 0.61 +/- 0.28 and 0.57 +/- 0.28 respectively. Of those with 1 month post-injection data (62.3%), the mean CMT decreased to 306 mum +/- 70 (p < 0.0001) in the Triesence group and 290 mum +/- 72 (p < 0.0001) in the Kenacort group, with mean VA of 0.40 +/- 0.28 (p = 0.0003) and 0.47 +/- 0.29 respectively (p = 0.2). The most common complication was ocular hypertension, which occurred in 13.0% of the Triesence group and 10.5% of the Kenacort group. Conclusion(s): Our preliminary analysis has found that intravitreal Triesence and Kenacort have a similar efficacy in improving mean visual acuity and central macular thickness at 1 month post-injection, with a similar complications profile. | Conference Start Date: | 2014-11-22 | Conference End Date: | 2014-11-26 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ceo.12446 | ISSN: | 1442-6404 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/42127 | Type: | Conference Abstract | Subjects: | laboratory macular edema retina vein occlusion medical audit *drug delivery system *Australian *New Zealand *college *ophthalmologist *human *intravitreal drug administration injection central macular thickness uveitis visual acuity diabetic macular edema Australia patient intraocular hypertension Populus triamcinolone acetonide *triamcinolone *college *ophthalmologist *human *intravitreal drug administration injection central macular thickness medical audit intraocular hypertension Populus patient uveitis retina vein occlusion macular edema laboratory *drug delivery system *Australian *New Zealand Australia diabetic macular edema visual acuity |
Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.